Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib for Unicentric Castleman Disease
NCT06643091Phase 2Not yet recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2024
- Primary completion
- May 2030
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of nintedanib in Castleman disease (CD), sponsored by Assistance publique - Hôpitaux de Paris. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
nintedanib
03
Conditions
Castleman disease (CD)
Beyond the preview
Go deeper on NCT06643091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06643091.